Carbapenemase OXA-423: A Novel OXA-23 Variant in Acinetobacter baumannii

Infection and Drug Resistance
Zhenghai YangXiaoning Li

Abstract

A novel variant of OXA-23, named OXA-423, was identified in an Acinetobacter baumannii clinical isolate. The aim of this study was to analyse the resistance phenotype of OXA-423. The A. baumannii strain WY-0713 was isolated from an intensive care unit patient. PCR was used to detect the blaOXA-23-like genes. Amplifying, cloning and sequencing were performed for the complete blaOXA-23-like. The novel blaOXA-423 and its ancestor blaOXA-23 were cloned into the expression vector pET-28b(+), and transformed into E. coli Rosetta (DE3) for antibiotic susceptibility testing. SDS-PAGE, modified Hodge test and CarbaNP test were used for detecting the expression of OXA-423 and OXA-23. PCR screening of A. baumannii WY-0713 was positive for blaOXA-23-like genes. Sequencing of the PCR product identified a novel blaOXA-23-like, named blaOXA-423 which encoding  OXA-423. OXA-423 differed from OXA-23 by a crucial amino acid substitution (Val128Ala). The V128A substitution was located at the conserved active-site motifs SAV of OXA-23. Antibiotic susceptibility testing performed using isogenic E. coli showed that the MICs of E. coli Rosetta (pET-OXA-423) for penicillins and carbapenems were lower (reduced MICs 4-fold to 16-fold) than that of E. col...Continue Reading

References

Jun 1, 1992·Molecular Microbiology·F CoutureR C Levesque
Mar 22, 2007·Proceedings of the National Academy of Sciences of the United States of America·Elena SantillanaAntonio Romero
Jan 16, 2008·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Mar 3, 2010·Antimicrobial Agents and Chemotherapy·Yu-Chi LinShu-Ying Li
Aug 5, 2017·Acta Crystallographica. Section D, Structural Biology·Marta TothSergei B Vakulenko
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Feb 28, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Roberto VivasSona Jain
May 28, 2019·Frontiers in Microbiology·Stefano GaiarsaRaffaele Zarrilli
Feb 28, 2020·Infection and Drug Resistance·Seyyed Naser AbdiHossein Samadi Kafil
May 10, 2020·Biomolecules·Maria Soledad RamirezMarcelo E Tolmasky

❮ Previous
Next ❯

Datasets Mentioned

BETA
KM433672

Methods Mentioned

BETA
PCR
X-ray

Software Mentioned

[UNK]
SWISS
BLAST
MODEL

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

Journal of Enzyme Inhibition and Medicinal Chemistry
Sinem Torol, Murat Kasap
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Abiola Olumuyiwa OlaitanJean Marc Rolain
© 2021 Meta ULC. All rights reserved